{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:30:48Z","timestamp":1786613448521,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01567-y","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:16:02Z","timestamp":1786612562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timing of Immune Checkpoint Inhibitor Initiation and Overall Survival in Advanced Gastric Cancer: A Multicenter Real-World Study Using Clone-Censor-Weight Analysis"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6660-9830","authenticated-orcid":false,"given":"Shota","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadamu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohiko","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akemi","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Shishido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Miyatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhisa","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"issue":"3","key":"1567_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"10251","key":"1567_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(20)31288-5.","journal-title":"Lancet"},{"issue":"8","key":"1567_CR3","doi-asserted-by":"publisher","first-page":"CD004064","DOI":"10.1002\/14651858.CD004064.pub4","volume":"8","author":"AD Wagner","year":"2017","unstructured":"Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):CD004064. https:\/\/doi.org\/10.1002\/14651858.CD004064.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"10060","key":"1567_CR4","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1016\/S0140-6736(16)30354-3","volume":"388","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654\u201364. https:\/\/doi.org\/10.1016\/S0140-6736(16)30354-3.","journal-title":"Lancet"},{"issue":"10294","key":"1567_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"2","key":"1567_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(21)00692-6.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1567_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1567_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10120-025-01698-4","volume":"29","author":"Japanese Gastric Cancer Association","year":"2026","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2025 (7th edition). Gastric Cancer. 2026;29(2):271\u201399. https:\/\/doi.org\/10.1007\/s10120-025-01698-4.","journal-title":"Gastric Cancer"},{"issue":"5","key":"1567_CR9","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","volume":"23","author":"JA Ajani","year":"2025","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23(5):169\u201391. https:\/\/doi.org\/10.6004\/jnccn.2025.0022.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10111","key":"1567_CR10","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5.","journal-title":"Lancet"},{"issue":"3","key":"1567_CR11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/bjc.2013.725","volume":"110","author":"CM Booth","year":"2014","unstructured":"Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110(3):551\u20135. https:\/\/doi.org\/10.1038\/bjc.2013.725.","journal-title":"Br J Cancer"},{"issue":"4","key":"1567_CR12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492\u20139. https:\/\/doi.org\/10.1093\/aje\/kwm324.","journal-title":"Am J Epidemiol"},{"issue":"8","key":"1567_CR13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol. 2016;183(8):758\u201364. https:\/\/doi.org\/10.1093\/aje\/kwv254.","journal-title":"Am J Epidemiol"},{"key":"1567_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"79","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Sauer BC, Hern\u00e1ndez-D\u00edaz S, et al. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70\u20135. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.04.014.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"1567_CR15","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1093\/ije\/dyaa057","volume":"49","author":"C Maringe","year":"2020","unstructured":"Maringe C, Benitez Majano S, Exarchakou A, et al. Reflection on modern methods: trial emulation in the presence of immortal-time bias. Assessing the benefit of major surgery for elderly lung cancer patients using observational data. Int J Epidemiol. 2020;49(5):1719\u201329. https:\/\/doi.org\/10.1093\/ije\/dyaa057.","journal-title":"Int J Epidemiol"},{"issue":"9","key":"1567_CR16","first-page":"1001","volume":"85","author":"T Onodera","year":"1984","unstructured":"Onodera T, Goseki N, Kosaki G. [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]. Nihon Geka Gakkai Zasshi. 1984;85(9):1001\u20135.","journal-title":"Nihon Geka Gakkai Zasshi"},{"issue":"1","key":"1567_CR17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJ Guthrie","year":"2013","unstructured":"Guthrie GJ, Charles KA, Roxburgh CS, et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218\u201330. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.03.010.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"1567_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1567_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/pds.1357","volume":"16","author":"S Suissa","year":"2007","unstructured":"Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16(3):241\u20139. https:\/\/doi.org\/10.1002\/pds.1357.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"1567_CR20","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"issue":"3","key":"1567_CR21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.tranon.2016.04.004","volume":"9","author":"J Wang","year":"2016","unstructured":"Wang J, Qu J, Li Z, et al. A prognostic model in metastatic or recurrent gastric cancer patients with good performance status who received first-line chemotherapy. Transl Oncol. 2016;9(3):256\u201361. https:\/\/doi.org\/10.1016\/j.tranon.2016.04.004.","journal-title":"Transl Oncol"},{"issue":"11","key":"1567_CR22","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(14)70420-6.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1567_CR23","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1093\/annonc\/mdt351","volume":"24","author":"HS Kim","year":"2013","unstructured":"Kim HS, Kim HJ, Kim SY, et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol. 2013;24(11):2850\u20134. https:\/\/doi.org\/10.1093\/annonc\/mdt351.","journal-title":"Ann Oncol"},{"issue":"6230","key":"1567_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","volume":"348","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56\u201361. https:\/\/doi.org\/10.1126\/science.aaa8172.","journal-title":"Science"},{"issue":"26","key":"1567_CR25","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1200690.","journal-title":"N Engl J Med"},{"key":"1567_CR26","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1200\/PO.21.00108","volume":"5","author":"PS Kok","year":"2021","unstructured":"Kok PS, Yoon WH, Lord S, et al. Tumor response end points as surrogates for overall survival in immune checkpoint inhibitor trials: a systematic review and meta-analysis. JCO Precis Oncol. 2021;5:1151\u20139. https:\/\/doi.org\/10.1200\/PO.21.00108.","journal-title":"JCO Precis Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01567-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:16:03Z","timestamp":1786612563000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01567-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1567"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01567-y","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the institutional review boards of the participating institutions: Tottori University Hospital ethics committee (approval number 19A136), Japanese Red Cross Tottori Hospital ethics committee (approval number 82), Matsue City Hospital ethics committee (approval number 2B-0005), Masuda Red Cross Hospital medical ethics committee (approval number 74), Yonago Medical Center ethics committee (approval number 0204-03), Hamada Medical Center ethics committee (approval number 3071), Tottori Prefectural Central Hospital ethics committee (approval number 2020-1), Tottori Rrefectural Kousei Hospital ethics committee (approval number 208), and Sanin Rosai Hospital ethics committee (approval number 2020-12). The requirement for informed consent was waived due to the retrospective nature of the study.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was waived because of the retrospective nature of the study.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"183"}}